Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III first-line study of sosimerasib sulfate + IN10018 versus tislelizumab + platinum-pemetrexed in KRAS G12C-mutated advanced nonsquamous non-small cell lung cancer
CTR20263527Phase 3Active
- Sponsor
- Zhejiang Hangyu Pharmaceutical
- Start
- Sep 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ifebemtinib, tislelizumab, pemetrexed, carboplatin in non-small cell lung cancer (NSCLC), sponsored by Zhejiang Hangyu Pharmaceutical. Started Sep 2026; status: active.
02
Drugs
ifebemtinibtislelizumabpemetrexedcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20263527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263527.